The FDA Hands the White House a Stinging Defeat on Its Covid Vax Plan

The Food and Drug Administration’s advisery panel on Friday rejected the Biden administration’s plan to offer booster shots of the Pfizer-BioNTech Covid vaccine to those age 16 and older. The FDA’s Vaccines and Related Biological Products Advisory Committee delivered the Biden proposal a stinging defeat of 16–2. However, the vote was non-binding and a final FDA vote is forthcoming.

“Over several hours of discussion, members of the Food and Drug Administration panel of outside experts voiced frustration that Pfizer had provided little data on safety of extra doses,” the Associated Press reported. “And they complained that data provided by Israeli researchers about their booster campaign might not be suitable for predicting the U.S. experience.”

“It’s unclear that everyone needs to be boosted, other than a subset of the population that clearly would be at high risk for serious disease,” Michael Kurilla, a committee member with the National Institutes of Health, said.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Send this to a friend